…heart disease remains the No. 1 killer in America; nearly half of all Americans have high blood pressure, high cholesterol, or smoke—some of the leading risk factors for heart disease…
—Murphy et al., 2018
Despite the high mortality rates associated with cardiovascular disorders, improved treatment options do exist that can help address those risk factors that afflict the majority of the population today.
As an advanced practice nurse, it is your responsibility to recommend appropriate treatment options for patients with cardiovascular disorders. To ensure the safety and effectiveness of drug therapy, advanced practice nurses must consider aspects that might influence pharmacokinetic and pharmacodynamic processes such as medical history, other drugs currently prescribed, and individual patient factors.
Reference: Murphy, S. L., Xu, J., Kochanek, K. D., & Arias, E. (2018). Mortality in the United States, 2017. Retrieved from https://www.cdc.gov/nchs/products/databriefs/db328…
To Prepare
Write a 2- to 3-page paper that addresses the following:
Case Study :
Patient CB is an 88 year-old female with a history of strokes. The patient has been diagnosed with type 2 diabetes, hypertension, and hyperlipidemia. Drugs currently prescribed include the following:
Learning Resources
Required Readings (click to expand/reduce)
Rosenthal, L. D., & Burchum, J. R. (2018). Lehne’s pharmacotherapeutics for advanced practice providers. St. Louis, MO: Elsevier.
Chapter 34, “Review of Hemodynamics†(pp. 335–340)
Chapter 35, “Diuretics†(pp. 341–349)
Chapter 36, “Drugs Acting on the Renin-Angiotensin-Aldosterone System†(pp. 351–362)
Chapter 37, “Calcium Channel Blockers†(pp. 363–369)
Chapter 38, “Vasodilators†(pp. 371–373)
Chapter 39, “Drugs for Hypertension†(pp. 375–388)
Chapter 40, “Drugs for Heart Failure†(pp. 389–402)
Chapter 41, “Antidysrhythmic Drugs†(pp. 403–418)
Chapter 42, “Prophylaxis of Atherosclerotic Cardiovascular Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels†(pp. 419–439)
Chapter 43, “Drugs for Angina Pectoris†(pp. 441–450)
Chapter 44, “Anticoagulant and Antiplatelet Drugs†(pp. 451–472)